65,437 trials
Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Recurrent Ovarian Carcinoma
Primary: Patients Who Survive Progression-free for at Least 6 Months — 6; 14 Participants
Metastatic Breast Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) — 19.7 Percentage of participants
Hepatic Veno-Occlusive Disease
Primary: Survival by Day+100 Post Stem Cell Transplant or Chemotherapy — 49.9 Percentage of participants alive
Age-related Macular Degeneration
Primary: Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day) — 5.720; -25.833 pg/mL
Legionnaires' Disease · Legionella Pneumophila Infections
Primary: Number of Participants With Treatment-Related Adverse Events — 2; 0 Participants
Suture Strabismus Surgery
Primary: Suture Colonization Rate in Adjustable Suture Strabismus Surgery — 57; 47 percentage sutures positive for bacteria
Acute Myeloid Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndrome (MDS)
Primary: Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) — 0.6; -1.2; 4.3; 5.3 msecs
Solid Organ Transplant Recipient (Liver, Kidney, Heart) · Rheumatologic Disorder · Human Immunodeficiency Virus (HIV)
Primary: Number of Episodes of Influenza and Influenza-Like-Illness Reported in High Dose and Standard Dose Vaccination Groups — 1; 1; 0; 0 episodes of illness
Health Behavior
Primary: Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use — 4.30; 4.11; 8.66; 8.77 ng/ml
Obesity
Primary: Change in PAI-1 Level — 39.5; 31.6; 28.6; 37.9 ng/ml — p=0.0005
Candidemia · Other Forms of Candida Infections(Intra-abdominal Abscess, Peritonitis)
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 141; 102 Participants
Unilateral Primary Osteoarthritis of Knee · Primary Osteoarthritis of Knee Nos
Primary: Self-Reported Pain With Movement — 9.5; 10; 14 scores on a scale — p=0.016
Small Cell Prostate Cancer · Neuroendocrine Prostate Cancer · Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers
Primary: Response Rate, as Assessed by CT/MRI and Bone Scan, of Treatment With MLN8237 for Patients With Neuroendocrine Prostate Cancer — 18 participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants